Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024

LONDON, June 27, 2014 /PRNewswire/ --

Epigenetics market  - new analysis showing you technological trends and sales forecasts
Do you want to find sales potentials of epigenetic technologies, diagnostics and medicines? Now get the latest analysis for that industry. There you explore developments (R&D), results, opportunities, trends and revenue forecasts.

Visiongain's updated report shows you what's possible for those drugs, diagnostic tests and related technology. Avoid missing out in data. Instead find progress in that industry and market, discovering expected advances and sales rises. See now how you can gain.

Assess technologies, products and services, benefiting your reputation for technological, medical and commercial insight. Read on, then, to explore that market and see its potential.

Forecasts and other information showing technical, clinical and business prospects
That new study gives you sales predictions to 2024 at overall world market, submarket, product and national level. See what the future holds for that emerging industry. For epigenetics you investigate where demand, opportunity and money lie.

Epigenetic uses hold great potential for diagnosing and treating diseases, including cancer.

There hear what's possible. And avoid struggles to find information. Besides giving revenue predictions, our analysis shows historical results, growth rates and market shares.

In that work you discover 72 tables, 57 charts and an interview. There help your research, analyses and decisions, also benefiting your influence and staying ahead.

And the following sections explain what our new investigation gives.

World market and its segments - what revenues possible from 2014 to 2024?
What's the commercial potential of epigenetics? Find in our report overall world revenue to 2024 for those products and technologies.

Also find individual revenue predictions to 2024 for three epigenetic submarkets at world level:
• Therapies
• Technologies for research
• Diagnostics

What're the secrets of progress? There you assess outlooks for trade expansion, hearing where you could benefit. That work investigates products, uses and rising sales. You find commercial prospects.

That study also predicts and discusses leading epigenetic medicines' sales potentials.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Revenue predictions for leading drugs and expected therapies
Our study forecasts revenues of top brands - four leading agents and two therapies awaiting launch. There you see individual revenue forecasts to 2024 for these products:
• Vidaza
• Dacogen
• Zolinza
• Istodax

And you gain predictions for these expected treatments:
• Beleodaq
• Faridak

There you explore drugs and years with highest predicted sales. Also you examine competitors. You see what's happening there, understanding, challenges, trends and outlooks.

For that overall market, the report also shows geographical revenue predictions.

Sales in leading national markets - what outlooks for epigenetics?
Advances in pharmaceuticals, biotechnology and healthcare expand use of epigenetic services and products. See their prospects in developed and developing regions.

Our analyses show you individual revenue forecasts to 2024 for eight national markets and two regions:
• United States (US)
• Japan
• Canada
• Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India and China (BRIC nations, grouped analysis).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain. The study explains, helping you stay ahead.

Also how do events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies and trends.

Strengths, challenges and events - what affects epigenetics?
The report explains issues, events and research and development (R&D) affecting that industry and market from 2014, including these forces:
• Uses for epigenetics in cancer, inherited disorders and neurological diseases
• DNA methlytransferase (DNMT) inhibition
• Histone deacetylase (HDAC) inhibitors
• Drug discovery and development using epigenetics
• Bisulphite screening for DNA methylation.

And you explore these influences and opportunities, among others:
• Chromatin immunoprecipitation (ChIP) for histone modification
• Chemogenic approaches to spatiotemporal regulation of HDAC activity
• Lysine pathways and acetylation-independent mechanisms
• DNMT inhibition and targeting other epigenetic enzymes
• Applications of genomics, proteomics and metabolomics
• Targeting orphan diseases and subpopulations - personalised and stratified medicine.

You explore what progress, trends and prospects mean. And you discover what benefits and restrains companies, affecting commercial performance. So what does the future hold?

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Epigenetics - leading companies and 2018 market value
From 2014, applications of epigenetics hold great potential for investments, technological advances and sales. What happens next?

Our new report predicts the world market for those products and technologies will reach $4,279m in 2018, with high further sales growth to 2024.

There you also see what organisations shape that industry:
• Celgene
• Eisai
• Roche
• Janssen-Cilag
• Otsuka Pharmaceuticals
• Merck & Co.

You also assess activities of these firms:
• TopoTarget
• Syndax Pharmaceuticals
• MDxHealth
• Epigenomics
• Life Technologies
• Qiagen, 4SC, EMD Millipore, Orion Genomics, DiscoveRx, EpiTherapeutics and others.

R&D in that industry holds strengths. And from 2014 there will arise many opportunities. From this decade onwards, patients, payers and companies will benefit. See how.

Ways Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024 helps
In three main ways our investigation helps your work:
• Revenues to 2024 at overall world level, for 3 submarkets and 6 products - assess outlooks for development, production, marketing and sales
• Forecasts to 2024 for eight national markets and two regions - investigate developed and developing countries for revenues and sales expansion
• Prospects for established competitors, rising companies and new entrants - explore products, R&D, opinions, and outlooks for success.

Knowledge there found nowhere else, benefiting your research, analyses and plans
Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where business prospects are most rewarding.

With that investigation you're less likely to fall behind in data or miss opportunity. Discover there how you can benefit your information searches, analyses and decisions. Also find how you could save time and gain in authority.

Our new study is for everyone assessing the present and future of epigenetics. Your choosing that analysis shows you results, trends, opportunities and sales predictions. So discover potential gains by getting that report here now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100 Or click on https://www.visiongain.com/Report/1284/Epigenetic-R-D-Therapies-and-Diagnostics-Industry-and-Market-Prospects-2014-2024

Companies Listed in this report 

4SC
Abbott Laboratories (AbbVie)
Accelerate Brain Cancer Cure
Accium BioSciences
Acetylon Pharmaceuticals
Active Motif
Agence Nationale de la Recherche (ANR)
Agilent
American Association of Cancer Research (AACR)
American Cancer Society
American Medical Association
American Society of Clinical Oncology
American Society of Hematology
Amgen
ARUP Laboratories
Astellas Pharma
Astellas Venture Management
Astex Pharmaceuticals (Otsuka Pharmaceutical)
AstraZeneca
Aton Pharma (now part of Merck & Co.)
Australian Alliance for Epigenetics
Automation Partnership
Babraham Institute
Baxter
Bayer
BGI
BioAlliance Pharma SA
BioChain
Biogen Idec
BioMarin Pharmaceuticals
BioSeek
Biotech Research and Innovation Centre
Biotechnology and Biological Sciences Research Council
BLUEPRINT Epigenome Consortium
Boehringer Mannheim
Bristol-Meyers Squibb
Bundesministerium für Bildung und Forschung (BMBF)
Cambridge Institute for Medical Research
Cambridge University
Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC)
Canadian Institute for Health Research (CIHR)
CanAm Bioresearch
Cancer Research Technology
Cancer Research UK
Celgene
CellCentric
Celleron Therapeutics
Cellzome
Center for Genomic Sciences (CGS)
Centre for Addiction and Mental Health (Canada)
Centre for Cancer Research
Centre for Genomic Regulation (Barcelona)
Centre National de la Recherche Scientifique (CNRS)
Ceptaris Therapeutics
ChemRar High Tech Center
Chiron
Chroma Therapeutics
City of Hope Medical Centre
Clavis Pharma
Committee for Medicinal Products for Human Use (CHMP)
Constellation Pharmaceuticals
Cornell University
CURELUNG
Curis
Cyclacel Pharmaceuticals
Dana-Farber Cancer Institute
Diagenode
DiscoveRX
Domainex
Dr. Reddy's Laboratories
Durviz
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
Eisai
Eli Lilly
Elixir Pharmaceuticals
EMD Millipore (also known as Merck Millipore)
EnVivo Pharmaceuticals (now part of Forum Pharmaceuticals)
EpigenDx
EpiGeneSys
Epigenetics Dream Team
Epigenomics
Epigentek
Epiontis
EpiTherapeutics
Epizyme
e-Therapeutics
European Commission (EC)
European Institute of Oncology (IEO)
European Medicines Agency (EMA)
European Patent Office
Exact Sciences
Experimental Cancer Medicine Network (ECMC)
FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee
Federal Ministry of Education and Research (BMBF)
FIRC Institute of Molecular Oncology Foundation (IFOM)
Flagship Biosciences
Forum Pharmaceuticals
Fresenius Kabi
Friedreich's Ataxia Research Alliance (FARA)
Genentech
Genpathway
German Cancer Research Center
GlaxoSmithKline (GSK)
Gloucester Pharmaceuticals (now part of Celgene)
Go FAR (Friedreich's Ataxia Research)
Harvard University
Health Canada
Health Genomics
Heptares Therapeutics
Hospital of Soochow University
Howard Hughes Medical Institute
Ignyta
IkerChem
Imperial College London
Indian Institute of Science Education and Research
Institute of Cancer Research
International Human Epigenome Consortium (IHEC)
Italfarmaco
Italian Institute of Technology (IIT)
Ivax LLC
Janssen Cilag
Janssen Pharmaceutica NV
Japan Science and Technology Agency (JST)
Japanese Society for Epigenetics
Jian-Xian Janssen Pharmaceuticals Ltd.
Johns Hopkins University
Kainos Medicine
Karus Therapeutics
Kindstar
King's College London
Krembil Family Epigenetics Laboratory
Kyowa Hakko Kirin Pharma Inc.
LabCorp
Leukemia & Lymphoma Society
Life Technologies' (now part of Thermo Fisher Scientific)
Louis Pasteur University of Strasbourg
Lundbeckfond Ventures
M.D. Anderson Cancer Center
Massachusetts General Hospital
Mayo Clinic
McGill University
MDxHealth
Medical Research Council
MEI Pharma
Memorial Sloan-Kettering Cancer Center
Merck & Co.
Merck KGaA
Merck Serono Ventures
MethylGene
MGI Pharma
Michael J. Fox Foundation for Parkinson's Research
Microgenics
Millennium Pharmaceuticals
MIMR-PHI Institute of Medical Research
Ministry of Health, Labour and Welfare (MHLW)
Mirati Therapeutics
MiReven
Mirna Therapeutics
Mitomics
Mount Sinai Medical Center
Multiple Myeloma Research Foundation
Muscular Dystrophy Association (MDA)
Myeloma UK
Myriad Genetics
National Ataxia Foundation (NAF)
National Cancer Institute
National Comprehensive Cancer Network (NCCN)
National Council of Science and Technology
National Health and Medical Research Council (NHMRC)
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute for Mental Health
National Institute of Allergy and Infectious Disease (NIAID)
National Institute of Cancerología
National Institute of Health, Korea
National Institute of Mental Health
National Institutes of Health (NIH)
National Institutes of Health Clinical Center (CC)
NewVac
NIH Epigenomics Roadmap Project
Nippon Shinyaku
Nottingham University
Novartis
Novartis Institutes for BioMedical Research (NIBR)
Novo Nordisk
Nycomed
Odyssey Molecular
OncoMethylome (now MDxHealth)
Onxeo
Onyx Pharmaceuticals
Orion Genomics
Oryzon Genomics
Otsuka Pharmaceuticals
Oxford University
Oxford University Hospitals NHS Trust
Pacific Biosciences
Pfizer
Pharmacyclics
Pharmion by Pharmacia & Upjohn
Physician's Choice Laboratory Services
PLUS Diagnostics
Polymedco
Predictive Biosciences
PrognosDx Health
Project Management Agency with German Aerospace Center (PT-DLR)
Psicofarma S.A. de C.V.
Qiagen
Quest Diagnostics
Quest Laboratory
Regulus Therapeutics
Repligen
Resverlogix
Rexahn Pharmaceuticals
Roche
Roche's Translational Clinical Research Centre
Roswell Park Cancer Institute
S*BIO
SABiosciences
Salarius Pharmaceuticals
Sandoz
Sanofi
Santaris Pharma AS
Scottish Medicines Consortium (SMC)
Seattle Genetics Inc
Seed Capital
Servier
Shape Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Centre
Siena Biotech
Sigma-Aldrich
Spectrum Pharmaceuticals
Structural Genomics Consortium (SGC)
Swiss Life
SwitchGear Genomics
Syndax Pharmaceuticals
Sysmex
Taiho Pharmaceutical
Takeda Pharmaceutical Company
Tempero Pharmaceuticals
Tensha Therapeutics
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries
The Lymphoma Academic Research Organisation
Thermo Fisher Scientific
Thomas Jefferson University
TopoTarget
UK Funders Alliance
UK Technology Strategy Board
United States District Court
University College London (UCL)
University of Birmingham
University of California, Los Angeles (UCLA)
University of Chicago
University of Leeds
University of North Carolina
University of the Basque Country
University of Toronto
University of Edinburgh
US Food and Drug Administration (FDA)
US National Cancer Institute
Ventana Medical Systems
Warnex
Wellcome Trust
Wistar Institute
World Health Organization (WHO)
Yakult Honsha Co.
ZoBio

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com